Formulation approaches in mitigating toxicity of orally administrated drugs

References

• Lipinski C, Lombardo F, Dominy B, Feeney P. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997;23:3–25.
   Web of Science ®Google Scholar
• Todd M, Lin X, Stankowski L Jr, Desai M, Wolfgang G. Toxicity screening of a combinatorial library: correlation of cytotoxicity and gene induction to compound structure. J Biomol Screen 1999;4:259–268.
   PubMedGoogle Scholar
• Sinha V, De Buck S, Fenu LA, Smit J, Nijsen M, Gilissen R et al. Predicting oral clearance in humans: how close can we get with allometry? Clin Pharmacokinet 2008;47:35–45.
   PubMed Web of Science ®Google Scholar
• Lord P. Investigating drug-related toxic mechanisms using genomic. Am Pharm Outsourc 2006;7:35–39.
   Google Scholar
• Dixit R. What non-clinical toxicology and safety pharmacodynamic data are needed to accelerate Phase I-II clinical trials? Am Pharm Outsourc 2004;5:30–43.
   Google Scholar
• Wyman M. Medication administration through enteral feeding tubes. Cleveland Clinic, Pharmacotherapy update 2008:11.
   Google Scholar
• Trevaskis NL, Charman WN, Porter CJ. Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update. Adv Drug Deliv Rev 2008;60:702–716.
   PubMed Web of Science ®Google Scholar
• http://www.bio-medicine.org/medicine-technology/OREXIGEN-Therapeutics-Announces-Sustained-Release-Formulation-of-0AZonisamide-Shows-Improved-Tolerability-When-Compared-to-Immediate-0ARelease-Formula-393-2/
   Google Scholar
• Du Souich P. Modulation of drug response by rate of input into the body. Proc West Pharmacol Soc 1998;41:219–223.
   PubMedGoogle Scholar
• Cainazzo MM, Pinetti D, Savino G, Bartiromo M, Forgione A, Bertolini A. Pharmacokinetics of a new extended-release nifedipine formulation following a single oral dose, in human volunteers. Drugs Exp Clin Res 2005;31:115–121.
   PubMedGoogle Scholar
• Mansoor A, von Hagel Keefer L. The dangers of immediate-release nifedipine for hypertensive crises. P&T 2002; 27:362–368.
   Google Scholar
• Sansom L. Oral-extended-release products. Aust Prescr 1999;22:88–90.
   Google Scholar
• Brouwers J, Ingels F, Tack J, Augustijns P. Determination of intraluminal theophylline concentrations after oral intake of an immediate- and a slow-release dosage form. J Pharm Pharmacol 2005;57:987–996.
   PubMed Web of Science ®Google Scholar
• DeVane C. Immediate-release versus controlled-release formulations: pharmacokinetics of newer antidepressants in relation to nausea. J Clin Psychiatry 2003;64 Suppl 18:14–19.
   PubMedGoogle Scholar
• Perucca E. Extended-release formulations of antiepileptic drugs: rationale and comparative value. Epilepsy Curr 2009;9:153–157.
   PubMed Web of Science ®Google Scholar
• Del Cuvillo A, Mullol J, Bartra J, Davila I, Jauregui I, Montoro J et al.. Comparative pharmacology of H1 antihistamines. J Investig Allergol Clin Immunol 2006;16:3–12.
   PubMedGoogle Scholar
• Opie L, Messerli F. Nifedipine and mortality. Grave defects in the dossier. Circulation 1995;92:1068–1073.
   PubMed Web of Science ®Google Scholar
• Gabapentin Extended-Release - Depomed: Gabapentin ER, Gabapentin Gastric Retention. Gabapentin GR Drugs R D 2007;8:317–320.
   Google Scholar
• Nangia A. Drug Delivery Report spring/summer 2006. Technologies Overviews 2006;42–50.
   Google Scholar
• Kinsella T, Vielhuber K, Kunugi K, Schupp J, Davis TW, Sands H. Preclinical toxicity and efficacy study of a 14-day schedule of oral 5-iodo-2-pyrimidinone-2′-deoxyribose as a prodrug for 5-iodo-2′-deoxyuridine radiosensitization in U251 human glioblastoma xenografts. Clin Cancer Res 2000;6:1468–1475.
   PubMed Web of Science ®Google Scholar
• Pouton C. Lipid formulations for the oral administration of drugs: emulsions, microemulsions and self-emulsifying microemulsions. AAPS short course. Toronto 2002.
   Google Scholar
• Charman W. Lipids, lipophilic drugs, and oral drug delivery-some emerging concepts. J Pharm Sci 2000;89:967–978.
   PubMed Web of Science ®Google Scholar
• Holm R, Porsgaard T, Porter C, Høy C, Edwards G, Müllertz A et al. Lymphatic fatty acids in canines dosed with pharmaceutical formulations containing structured triacylglycerols. Eur J Lipid Sci Tech 2006;108:714–722.
   Google Scholar
• Santangelo R, Paderu P, Delmas G, Chen ZW, Mannino R, Zarif L et al. Efficacy of oral cochleate-amphotericin B in a mouse model of systemic candidiasis. Antimicrob Agents Chemother 2000;44:2356–2360.
   PubMed Web of Science ®Google Scholar
• Larabi M, Pages N, Pons F, Appel M, Gulik A, Schlatte J et al. Study of the toxicity of a new lipid complex formulation of amphotericin B. J Antimicrob Chemother 2004;53:81–88.
   PubMed Web of Science ®Google Scholar
• Malingre M, Terwogt J, Beijnen J, Rosing H, Koopman FJ, van Tellingen O et al. Phase I and pharmacokinetic study of oral paclitaxel. J Clin Oncol 2000;18:2468–2475.
   PubMed Web of Science ®Google Scholar
• Veltkamp S, Thijssen B, Garrigue J, Lambert G, Lallemand F, Binlich F et al. A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer. Br J Cancer 2006;95:729–734.
   PubMed Web of Science ®Google Scholar
• Hausheer F, Dodd T. Formulations and methods for reducing toxicity of antineoplastic agents. US application number 08/954,678.
   Google Scholar
• Uchida M, Matsueda K, Shoda R, Muraoka A, Yamato S. Nitric oxide donating compounds inhibit HCl-induced gastric mucosal lesions mainly via prostaglandin. Jpn J Pharmacol 2001;85:133–138.
   PubMedGoogle Scholar
• Kato S, Suzuki K, Ukawa H, Komoike Y, Takeuchi K. Low gastric toxicity of nitric oxide-releasing aspirin, NCX-4016, in rats with cirrhosis and arthritis. Dig Dis Sci 2001;46:1690–1699.
   PubMedGoogle Scholar
• Richards A, Pope N. Composition comprising d-threo-methylphenidate and another drug. Patent GB 95-14450.
   Google Scholar
• Podolin P, Web E, Reddy M, Truneh A, Griswold D. Inhibition of contact sensitivity in human CD4+ transgenic mice by human CD4-specific monoclonal antibodies: CD4+ T-cell depletion is not required. Immunology 2000;99:287–295.
   PubMed Web of Science ®Google Scholar
• Moses A. Gastro retentive dosage form. Crit Rev Ther Drug Carrier Syst 1993;10:143–195
   PubMedGoogle Scholar
• Welling P. Effects of food on drug absorption. Pharmacol Ther 1989;43:425–441.
   PubMedGoogle Scholar
• Cattaneo M, Luong J. A stable water-soluble tetramethylbenzidine-2-hydroxypropyl-beta-cyclodextrin inclusion complex and its applications in enzyme assays. Anal Biochem 1994;223:313–320.
   PubMed Web of Science ®Google Scholar
• Manessis A, Lascher S, Bukberg P, Darmody T, Yen V, Sadek S et al. Quantifying amount of adsorption of levothyroxine by percutaneous endoscopic gastrostomy tubes. JPEN J Parenter Enteral Nutr 2008;32:197–200.
   PubMedGoogle Scholar
• Uno Y, Yasui-Furukori F. Effect of grapefruit juice in relation to human pharmacokinetic study. Curr Clin Pharmacol 2006;1:157–161.
   PubMedGoogle Scholar
• Bailey DG. Fruit juice inhibition of uptake transport: a new type of food-drug interaction. Br J Clin Pharmacol 2010;70:645–655.
   PubMed Web of Science ®Google Scholar